| Autor: |
Ganguly, Swagata, Saha, Pabitra, Guha, Subhasish K., Das, Sonali, Bera, Dilip K., Biswas, Asit, Kundu, Pratip K., Saha, Bibhuti, Ray, Krishnangshu, Maji, Ardhendu K. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; December 2012, Vol. 57 Issue: 3 p1246-1251, 6p |
| Abstrakt: |
ABSTRACTPlasmodium vivaxmalaria, though benign, has now become a matter of concern due to recent reports of life-threatening severity and development of parasite resistance to different antimalarial drugs. The magnitude of the problem is still undetermined. The present study was undertaken to determine the in vivoefficacy of chloroquine (CQ) and chloroquine plus primaquine in P. vivaxmalaria in Kolkata and polymorphisms in the pvmdr1and pvcrt-ogenes. A total of 250 patients with P. vivaxmonoinfection were recruited and randomized into two groups, A and B; treated with chloroquine and chloroquine plus primaquine, respectively; and followed up for 42 days according to the WHO protocol of 2009. Data were analyzed using per-protocol analyses. We assessed polymorphisms of the pvmdr1 and pvcrt-ogenes by a DNA-sequencing method. Out of the 250 patients recruited, 204 completed a 42-day follow-up period, 101 in group A and 103 in group B. In group A, the non-PCR-corrected efficacy of CQ was 99% (95% confidence interval [CI], 0.944 to 1.00), and in group B, all cases were classified as adequate clinical and parasitological response (ACPR). Day 3 positivity was observed in 11 (5.3%) cases. No specific mutation pattern was recorded in the pvcrt-ogene. Eight nonsynonymous mutations were found in the pvmdr1gene, three of which were new. The Y976F mutation was not detected in any isolate. Chloroquine, either alone or in combination with primaquine, is still effective against P. vivaxmalaria in the study area. (The study protocol was registered in CTRI [Clinical Trial Registry-India] of the Indian council of Medical Research under registration no. CTRI/2011/09/002031.) |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
